Quick Answer
NeuroSense Therapeutics Ltd. reported R&D Expense of $6.23 million for fiscal year 2025.
NeuroSense Therapeutics Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.23M | +9.3% |
| 2024 | $5.70M | -21.7% |
| 2023 | $7.27M | +30.2% |
| 2022 | $5.59M | — |
- NeuroSense Therapeutics Ltd. showed an increase of +9.3% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, NeuroSense Therapeutics Ltd.’s r&d expense has grown by 11.5% (from $5.59 million to $6.23 million).
- The most recent figure is from NeuroSense Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: